Back to search

Ireland· IE-PA-PA1353/005/001

Embesin 20 IU/ml concentrate for solution for infusion

A vasopressin (argipressin) product containing argipressin, registered in Ireland by Orpha-Devel Handels und Vertriebs GmbH. The same ATC class is registered in 10 of our 19 countries.

ATC H01BA01

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedEmbesin 20 IU/ml concentrate for solu…ATCH01BA01REGISTER NO.IE-PA-PA1353/005/001PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Vasopressin (argipressin) is registered in 10 of 19 countries.

Countries holding a registration under ATC H01BA01 (vasopressin (argipressin)), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 6 of them publish a price we can compare per daily dose

Vasopressin (argipressin) · ATC H01BA01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Argipressin
Manufacturer
Orpha-Devel Handels und Vertriebs GmbH
Country
Ireland (IE)
ATC code
H01BA01
ATC class
Vasopressin (argipressin)
Defined daily dose
40 E, P
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA1353/005/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

166 interactions on record for vasopressin (argipressin).

Graded by severity as the source publishes them — 39 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Vasopressin (argipressin) · interactions on record

166 records

  • 39 severe
  • 125 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Vasopressin (argipressin) in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All vasopressin (argipressin) products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Empesin
  • Belgium · Reverpleg
  • Bulgaria · Емпресин
  • Czechia · Embesin
  • Germany · Argipressin Farmak, Empressin
  • Denmark · Empressin
  • Estonia · Empesin
  • Spain · Empressin
  • Finland · Empressin
  • France · Reverpleg
  • United Kingdom (Northern Ireland) · Argipressin Aop, Argipressin Mercury Pharmaceuticals
  • Greece · Empressin
  • Croatia · Empressin
  • Hungary · Embesyn
  • Italy · Empressin
  • Lithuania · Empesin
  • Luxembourg · Reverpleg
  • Latvia · Empesin
  • Netherlands · Empressine
  • Norway · Empressin
  • Poland · Argipressin Farmak, Empesin
  • Portugal · Empressin
  • Romania · Reverpleg
  • Sweden · Empressin
  • Slovenia · Empesin
  • Slovakia · Embesin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/de815218-1776-44cf-b2c5-962cee757d2c
GET /v1/drugs/de815218-1776-44cf-b2c5-962cee757d2c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentrate for solution for infusion",
  "routes": [
    "Intravenous use"
  ],
  "source": "hpra",
  "atc_all": [
    "H01BA",
    "H01BA01"
  ],
  "strength": null,
  "pa_number": "PA1353/005/001",
  "substances": [
    "Argipressin"
  ],
  "legal_basis": "Well-established use application (Article 10a of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "23/03/2018",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about vasopressin (argipressin).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.